Asian Journal of Medical Sciences
June 30, 2026
Raja Suhail Shounthoo, Ajaiz Rasool, Athar Un Nisa Quraishi et al.
Ketamine, a dissociative anesthetic introduced in the 1960s, has re-emerged as a versatile therapeutic agent extending beyond its traditional perioperative role. Its rapid antidepressant action in treatment-resistant depression and efficacy in acute and chronic pain syndromes have driven what is termed the “ketamine renaissance.” Unlike conventional monoaminergic antidepressants, ketamine...
Pharmacology, biochemistry, and behavior
June 30, 2026
Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...
Zenodo (CERN European Organization for Nuclear Research)
June 28, 2026
Giulio Ruffini, Francesca Castaldo
Pharmacological neuroplastogens---psychedelics, ketamine, MDMA---open transient windows of enhanced neural plasticity that can catalyze therapeutic change in mood disorders and beyond. Their clinical promise, however, is constrained by safety concerns, regulatory barriers, and unsuitability for vulnerable populations such as adolescents. Here we argue, from first principles within the...
J Psychopharmacol
June 28, 2026
Yingjie Du, Xiangting Zhao, Yishan Yao et al.
BACKGROUND: Posttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by...
Zenodo (CERN European Organization for Nuclear Research)
June 24, 2026
Ramiro Solis
The brain’s ability to rewire itself, neuroplasticity, declines dramatically with age. Children learn faster; adults get stuck in patterns; older adults struggle to adapt. The reasons for this decline remain unclear. In a companion paper (Solis, 2026a), I critically evaluated the broad hypothesis that N,N-dimethyltryptamine (DMT) has endogenous physiological functions. The evidence was found to...
Progress in neuro-psychopharmacology & biological psychiatry
June 20, 2026
Agnieszka Bysiek, Izabela Szpręgiel, Adam Wojtas et al.
Psychedelics have emerged as a promising novel therapeutic approach for major depressive disorder (MDD). Altered activity and structural atrophy of the prefrontal cortex, hippocampus, and limbic structures are associated with depressive disorders. Psilocybin may reverse the loss of synaptic connections and restore the function of these brain regions. In this study, we investigated the effects...
Progress in neuro-psychopharmacology & biological psychiatry
June 20, 2026
Zhen Xuen Brandon Low
Autism Spectrum Disorder (ASD) is characterized by persistent social-communication deficits, cognitive rigidity, and atypical sensory processing. Current pharmacological treatments, including risperidone and aripiprazole, provide only limited symptomatic relief and do not address the underlying neurobiological mechanisms. Converging evidence implicates dysregulated serotonergic signaling,...
Clinical drug investigation
June 13, 2026
Angel Prabakar
Ketamine has revolutionized the treatment of mood disorders by offering rapid antidepressant effects, particularly in individuals with treatment-resistant depression. Unlike traditional monoaminergic antidepressants, ketamine acts primarily through antagonism of the N-methyl-D-aspartate (NMDA) receptor, initiating a cascade of glutamatergic signaling that promotes synaptic plasticity,...
Pharmacological Reports
June 12, 2026
Wojciech Ziemichód, Natalia Kajka, Klaudia Kister et al.
The glutamatergic system, particularly N-methyl-D-aspartate (NMDA) receptors, has long been a significant focus of research into new strategies for treating depression, and the clinical success of ketamine, an NMDA receptor antagonist, has been a significant breakthrough. In parallel, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, another key component of the...
Neurosci Biobehav Rev
June 7, 2026
Yoav Domany, Aviv Solomon-Shashua
Suicide, the individual desire to take one's own life, at whose core lies the unbearable psychological pain Shneidman called psychache, is a uniquely human experience. Unlike depression, suicidality has no preclinical analog. Suicidality and chronic depression, long treated as a single clinical entity, are increasingly recognized as partly separable in neurobiology and treatment response....
Translational Psychiatry
June 5, 2026
Samaneh Ahmadian-Moghadam, Shiva Roshan-Milani, Ehsan Saboory
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition in which prenatal stress and long-lasting disruptions of excitatory-inhibitory (E/I) balance have been implicated as key vulnerability factors. Although established pharmacological and behavioral treatments are effective for many individuals, they are not universally successful and do not directly target...
Zenodo (CERN European Organization for Nuclear Research)
June 5, 2026
Mark D. Nicolas
Dominant psychedelic frameworks have been developed primarily from acute-phase neuroimaging and emphasize transient network reconfiguration during the drug state. Less attention has been given to the post-acute period, during which consequential electrophysiological and clinical changes may unfold. Ibogaine, whose human evidence is restricted to the post-acute window, provides a particularly...
Cureus
June 1, 2026
Hoi Ki Cheung, Ngo Cheung
A proportion of patients with obsessive-compulsive disorder (OCD) continue to experience disabling symptoms despite standard serotonergic treatment, antipsychotic augmentation, and psychological input. Contamination-focused OCD can be especially persistent when rituals are embedded in the home environment and reinforced by family patterns. Recent work has drawn attention to glutamatergic...
Asian Journal of Psychiatry
June 1, 2026
Hariprasad Ganapathy Vijayakumar, Varsha Shamanna, Harsh Pathak et al.
1 citation
Treatment resistance in bipolar depression is one of the most challenging clinical conditions to treat in psychiatry. We present a case of an elderly gentleman with chronic Multi-Therapy Resistant Bipolar Depression (MTRBD), where ketamine, a preferential NMDAR blocker on cortical GABAergic interneurons, is used adjunctively with sequential theta burst stimulation (sTBS) to achieve remission....
Biomedicines
June 1, 2026
Masaru Tanaka
Major depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief. Rapid-acting antidepressants reshaped the field by linking swift symptom improvement to glutamatergic plasticity, yet durable benefit depends on how newly reconfigured circuits are stabilized and tuned. This review synthesizes evidence...